Charles River Laboratories International Inc
Charles River Laboratories International, Inc. is a global provider of solutions, which accelerate the early-stage drug discovery and development process. The focus of its business is in vivo biology; its portfolio includes research models and services required to enable in vivo drug discovery and development. The Company operates in two segments: Research Models and Services (RMS) and Preclinical Services (PCS). Through its RMS segment, the Company has been supplying research models to the drug development industry. The Company is engaged in the production and sale of rodent research model strains, principally genetically and microbiologically defined purpose-bred rats and mice. Its PCS business segment provides services that enable its clients to outsource their critical, regulatory-required safety assessment and related drug development activities to the Company. In August 2012, the Company acquired Accugenix, Inc. In January 2013, the Company acquired 75% ownership of Vital River.
Trading 4% above its estimated fair value of $161.69.
Current Price
$167.74
-9.23%GoodMoat Value
$161.69
3.6% overvaluedCharles River Laboratories International Inc (CRL) Stock Chart
CRL Interactive Stock Chart
Interactive stock chart for Charles River Laboratories International Inc (CRL) with candlestick and line chart views. Analyze price action across multiple timeframes: 5 days, 1 week, 1 month, 3 months, 6 months, 1 year, 5 years, and full history.
Current price: $167.74. 52-week high: $226.77. 52-week low: $114.66. 50-day moving average: $168.80. 200-day moving average: $175.68.
Technical analysis indicators include Volume, SMA 20, SMA 50, SMA 200, EMA 20, and RSI. Toggle between candlestick and line chart styles. Overlay multiple moving averages to identify support and resistance levels, trend direction, and momentum signals for CRL. Use the chart alongside GoodMoat's fundamental analysis tools for a complete picture of Charles River Laboratories International Inc's investment potential.